News stories about AbbVie (NYSE:ABBV) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.3014554849211 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

AbbVie (NYSE:ABBV) opened at $113.62 on Thursday. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. The stock has a market capitalization of $181,120.00, a price-to-earnings ratio of 27.58, a price-to-earnings-growth ratio of 1.04 and a beta of 1.61. AbbVie has a one year low of $60.05 and a one year high of $125.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.44 by $0.04. The firm had revenue of $7.74 billion during the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the company posted $1.20 EPS. equities research analysts predict that AbbVie will post 7.46 earnings per share for the current year.

ABBV has been the subject of a number of recent analyst reports. Cowen raised AbbVie from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $91.17 to $105.00 in a report on Wednesday, October 11th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research note on Friday, October 13th. Barclays increased their price target on AbbVie to $90.00 and gave the company an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group increased their price target on AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Finally, Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price target for the company in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $117.26.

In other news, EVP Michael Severino sold 25,633 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the sale, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at approximately $10,881,964.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the sale, the chairman now directly owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 476,376 shares of company stock valued at $45,580,873. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect AbbVie (ABBV) Share Price” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.